REQUEST A DEMO
Total
USD $0.00
Search more companies

Glaxo Smithkline Korea Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Glaxo Smithkline Korea Co.,Ltd. Profile Updated: January 24, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

Glaxo SmithKline Korea Co., Ltd. is engaged in manufacturing pharmaceutical and healthcare products. The company's product portfolio includes Sensodyne, Voltaren, Theraflu, Parodontax, Panadol, Polident and Otrivin, vaccines, HIV treatment and dermatology medicines. Glaxo SmithKline Korea Co., Ltd. is based in Seoul, South Korea. The company was established in 1986 and operates as a subsidiary of GlaxoSmithKline PLC.

Headquarters
92, Hangang-daero Yongsan-gu Seoul
Seoul; Seoul; Postal Code: 140012

Contact Details: Purchase the Glaxo Smithkline Korea Co.,Ltd. report to view the information.

Website: http://www.gsk-korea.co.kr

Basic Information
Total Employees:
Purchase the Glaxo Smithkline Korea Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Glaxo Smithkline Korea Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Glaxo Smithkline Korea Co.,Ltd. report to view the information.
Incorporation Date:
February 23, 1968
Key Executives
Purchase this report to view the information.
CEO
Ownership Details
Purchase this report to view the information.
95%
Purchase this report to view the information.
5%
Company Performance
Financial values in the chart are available after Glaxo Smithkline Korea Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-8.69%
Total operating revenue
-8.69%
Operating profit (EBIT)
306.35%
EBITDA
117.83%
Net Profit (Loss) for the Period
90.18%
Total assets
17.24%
Total equity
14.45%
Operating Profit Margin (ROS)
2.73%
Net Profit Margin
2.4%
Return on Equity (ROE)
4.02%
Debt to Equity Ratio
33.24%
Quick Ratio
-0.03%
Cash Ratio
0.05%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?